

Itch Relief and Quality of Life Improvement with Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE COMPARE and JADE DARE

Gil Yosipovitch,¹ Melinda J. Gooderham,^{2,3,4} Sarina B. Elmariah,⁵ Gianluca Bonfanti,⁶ Roger A. Edwards,⁷ Stamatios Gregoriou,⁸ Pinaki Biswas,⁹ Daniela E. Myers,⁹ Justine Alderfer,¹⁰ Erman Güler,¹¹ Christopher Koulias¹²

¹Miami Itch Center, Miller School of Medicine, University of Miami, Miami, FL, USA; ²Skin Centre for Dermatology, Peterborough, ON, Canada; ³Queen's University, Kingston, ON, Canada; ⁴Probit Medical Research, Waterloo, ON, Canada; ⁵University of California San Francisco, San Francisco, CA, USA; ⁶Engineering Ingegneria Informatica, Milan, Italy; ⁷Health Services Consulting Corporation, Boxborough, MA, USA; ⁸National and Kapodistrian University of Athens, Athens, Greece; ⁹Pfizer Inc., New York, NY, USA; ¹⁰Pfizer Inc., Collegeville, PA, USA; ¹¹Pfizer Inc., Istanbul, Turkey; ¹²Pfizer Hellas S.A., Athens, Greece

Corresponding author:

Gil Yosipovitch

Miami Itch Center, Miller School of Medicine, University of Miami, Miami, FL, USA

Phone: 305-243-4472

Email: yosipog@gmail.com

Supplementary Tables and Figures

Supplementary Table S1 Baseline disease characteristics by itch severity subgroup

	PP-NRS Score													
	4		5		6		7		8		9		10	
	Abrocitinib n = 20	Dupilumab n = 32	Abrocitinib n = 35	Dupilumab n = 49	Abrocitinib n = 75	Dupilumab n = 101	Abrocitinib n = 138	Dupilumab n = 125	Abrocitinib n = 160	Dupilumab n = 143	Abrocitinib n = 98	Dupilumab n = 90	Abrocitinib n = 57	Dupilumab n = 64
Age, median (IQR)	32.0 (24.0, 46.0)	30.5 (23.0, 40.0)	37.0 (26.0, 49.0)	31.0 (26.0, 49.0)	32.0 (24.0, 44.0)	34.0 (25.0, 47.0)	32.0 (24.0, 44.0)	31.0 (25.0, 41.0)	35.0 (26.5, 50.0)	31.0 (24.0, 46.0)	36.0 (26.0, 48.0)	33.5 (25.0, 47.0)	39.0 (28.0, 51.0)	35.0 (27.0, 44.0)
Female, n (%)	9 (45)	16 (50)	13 (37)	25 (51)	37 (49)	42 (42)	65 (47)	52 (42)	79 (49)	71 (50)	54 (55)	50 (56)	31 (54)	36 (56)
Race, n (%)^a														
White	15 (75)	21 (66)	29 (83)	39 (80)	51 (68)	66 (65)	100 (73)	95 (76)	123 (77)	100 (70)	67 (68)	63 (70)	41 (72)	38 (59)
Black	0	4 (13)	0	3 (6)	2 (3)	6 (6)	7 (5)	3 (2)	8 (5)	9 (6)	11 (11)	8 (9)	5 (9)	7 (11)
Asian	5 (25)	6 (19)	6 (17)	7 (14)	22 (29)	24 (24)	29 (21)	25 (20)	26 (16)	32 (22)	17 (17)	17 (19)	10 (18)	18 (28)
Other	0	1 (3)	0	0	0	5 (5)	2 (1)	2 (2)	3 (2)	1 (1)	3 (3)	1 (1)	1 (2)	1 (2)
Duration of AD, years, mean (SD)	22.1 (13.2)	23.3 (15.2)	24.7 (14.6)	27.1 (14.6)	26.1 (14.6)	25.5 (14.2)	23.7 (13.3)	22.1 (13.7)	23.0 (15.7)	22.4 (14.6)	24.1 (14.8)	22.3 (14.9)	24.2 (15.9)	25.7 (12.9)
IGA, n (%)														
3 (moderate)	14 (70)	26 (81)	24 (69)	40 (82)	58 (77)	71 (70)	89 (64)	78 (62)	97 (61)	95 (66)	48 (49)	42 (47)	21 (37)	28 (44)
4 (severe)	6 (30)	6 (19)	11 (31)	9 (18)	17 (23)	30 (30)	49 (36)	47 (38)	63 (39)	48 (34)	50 (51)	48 (53)	36 (63)	36 (56)
EASI, median (IQR)	20 (17, 30)	21 (18, 25)	22 (20, 36)	20 (18, 30)	24 (18, 32)	24 (20, 32)	26 (19, 34)	26 (19, 35)	25 (20, 35)	23 (19, 36)	27 (21, 39)	28 (20, 38)	30 (22, 44)	28 (19, 41)
%BSA, median (IQR)	35 (23, 54)	32 (22, 40)	43 (22, 61)	35 (21, 48)	38 (26, 53)	37 (28, 55)	41 (27, 58)	38 (23, 53)	39 (26, 60)	38 (23, 58)	44 (31, 63)	45 (29, 67)	46 (30, 63)	47 (29, 72)
DLQI, median (IQR)	8 (6, 14)	10 (6, 17)	10 (6, 14)	9 (6, 14)	13 (8, 16)	12 (9, 16)	13 (9, 19)	13 (10, 18)	17 (12, 21)	16 (11, 22)	18 (13, 21)	16 (12, 19)	18 (14, 26)	20 (16, 24)
POEM, median (IQR)	16 (10, 18)	17 (12, 22)	18 (13, 21)	18 (13, 21)	20 (15, 24)	19 (16, 24)	20 (16, 24)	20 (18, 24)	22 (19, 26)	23 (20, 26)	23 (20, 26)	23 (19, 27)	25 (21, 28)	26 (21, 28)

%BSA percentage of body surface area, *DLQI* Dermatology Life Quality Index, *EASI* Eczema Area and Severity Index, *IGA* Investigator's Global Assessment, IQR interquartile range, POEM Patient-Oriented Eczema Measure.

Data were analyzed in the Full Analysis Set, defined as all randomized patients who received at least one dose of study medication.

^aRace was reported by the patients.


Supplementary Table S2 Proportion of patients by individual PP-NRS scores at weeks 2, 12, and 16

PP-NRS score	Week 2		Week 12		Week 16	
	Abrocitinib 200 mg QD <i>N</i> = 588	Dupilumab 300 mg Q2W <i>N</i> = 608	Abrocitinib 200 mg QD <i>N</i> = 588	Dupilumab 300 mg Q2W <i>N</i> = 608	Abrocitinib 200 mg QD <i>N</i> = 588	Dupilumab 300 mg Q2W <i>N</i> = 608
	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
0/1 (itch-free state)	98 (16.7)	29 (4.8)	219 (37.2)	149 (24.5)	190 (32.3)	147 (24.2)
0	36 (6.1)	6 (1.0)	105 (17.9)	49 (8.1)	101 (17.2)	50 (8.2)
1	62 (10.5)	23 (3.8)	114 (19.4)	100 (16.5)	89 (15.1)	97 (16.0)
2	92 (15.6)	53 (8.7)	81 (13.8)	105 (17.3)	85 (14.5)	95 (15.7)
3	90 (15.3)	74 (12.2)	78 (13.3)	82 (13.5)	77 (13.1)	97 (16.0)
4	74 (12.6)	92 (15.2)	55 (9.4)	85 (14.0)	50 (8.5)	59 (9.7)
5	67 (11.4)	95 (15.7)	43 (7.3)	60 (9.9)	35 (6.0)	51 (8.4)
6	75 (12.8)	91 (15.0)	30 (5.1)	36 (5.9)	29 (4.9)	38 (6.3)
7	54 (9.2)	93 (15.3)	24 (4.1)	23 (3.8)	19 (3.2)	16 (2.6)
8	24 (4.1)	47 (7.7)	10 (1.7)	16 (2.6)	7 (1.2)	17 (2.8)
9	9 (1.5)	20 (3.3)	3 (0.5)	8 (1.3)	3 (0.5)	4 (0.7)
10	4 (0.7)	11 (1.8)	2 (0.3)	3 (0.5)	3 (0.5)	2 (0.3)

PP-NRS Peak Pruritus Numerical Rating Scale, Q2W once every 2 weeks, QD once daily.

Data were analyzed in the Full Analysis Set, defined as all randomized patients who received at least one dose of study medication.

Supplementary Figure S1 Proportion of patients achieving a daily PP-NRS score of <2 through week 2 by baseline itch severity.



PP-NRS Peak Pruritus Numerical Rating Scale.